Differential treatment resricted access to newer antiretrovirals [electronic resource] / Sarah Zaidi.
- New York : United Nations, 2012.
- Government document
1 online resource (4 pages)
- Local subjects:
- Public Health. (search)
- The discovery of antiretroviral (ARV) treatment for people living with HIV (PLHIV) is one of the best success stories of medical research in recent years. It has changed the way in which HIV is viewed-from that of a death sentence to a chronic illness. However, lifelong treatment requires constant access to newer drug regimens, as an HIV-infected person either develops serious side effects, or the virus becomes resistant to the drugs. While patients in developed countries have treatment options, the same cannot be claimed for those in developing countries. With more than twenty approved antiretroviral drugs, the global HIV drug market is estimated to approach $16 billion by 2016. Yet, not all ARVs, especially newer and more potent treatments, are licensed or available in every country, particularly in the global South. Why is there such a gap in access to treatment between industrialized and developing countries? Why are newer, more potent, less toxic ARVs not available to PLHIV in the global South? How can this growing disconnect between treatment options be altered?
- Contained In:
- UN Chronicle Vol. 48, no. 1, p. 26-29
- Access Restriction:
- Restricted for use by site license.
|Location||Notes||Your Loan Policy|
|Description||Status||Barcode||Your Loan Policy|